Roy EJ - Search Results

1

Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors.

Thomas DL, Kranz DM, Roy EJ. Thomas DL, et al. Among authors: roy ej. Cancer Immunol Immunother. 2008 Sep;57(9):1323-33. doi: 10.1007/s00262-008-0467-8. Epub 2008 Feb 16. Cancer Immunol Immunother. 2008. PMID: 18278494 Free PMC article.

2

A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors.

Gawlick U, Kranz DM, Schepkin VD, Roy EJ. Gawlick U, et al. Among authors: roy ej. Bioconjug Chem. 2004 Sep-Oct;15(5):1137-45. doi: 10.1021/bc049911e. Bioconjug Chem. 2004. PMID: 15366970

3

Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism.

Fan TM, Kranz DM, Roy EJ. Fan TM, et al. Among authors: roy ej. J Immunother. 2007 Jul-Aug;30(5):479-89. doi: 10.1097/CJI.0b013e318031a2b2. J Immunother. 2007. PMID: 17589288

4

Costimulatory strength influences the differential effects of transforming growth factor beta1 for the generation of CD8+ regulatory T cells.

Fan TM, Kranz DM, Flavell RA, Roy EJ. Fan TM, et al. Among authors: roy ej. Mol Immunol. 2008 May;45(10):2937-50. doi: 10.1016/j.molimm.2008.01.019. Epub 2008 Mar 5. Mol Immunol. 2008. PMID: 18321576

5

Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells.

Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ. Thomas DL, et al. Among authors: roy ej. J Immunol. 2009 Aug 1;183(3):1828-37. doi: 10.4049/jimmunol.0802322. Epub 2009 Jul 10. J Immunol. 2009. PMID: 19592642

6

Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Thomas DL, Doty R, Tosic V, Liu J, Kranz DM, McFadden G, Macneill AL, Roy EJ. Thomas DL, et al. Among authors: roy ej. Cancer Immunol Immunother. 2011 Oct;60(10):1461-72. doi: 10.1007/s00262-011-1045-z. Epub 2011 Jun 9. Cancer Immunol Immunother. 2011. PMID: 21656158 Free PMC article.

7

MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.

Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM. Soto CM, et al. Among authors: roy ej. Cancer Immunol Immunother. 2013 Feb;62(2):359-69. doi: 10.1007/s00262-012-1336-z. Epub 2012 Aug 25. Cancer Immunol Immunother. 2013. PMID: 22926060 Free PMC article.

8

A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.

Stone JD, Harris DT, Soto CM, Chervin AS, Aggen DH, Roy EJ, Kranz DM. Stone JD, et al. Among authors: roy ej. Cancer Immunol Immunother. 2014 Nov;63(11):1163-76. doi: 10.1007/s00262-014-1586-z. Epub 2014 Aug 1. Cancer Immunol Immunother. 2014. PMID: 25082071 Free PMC article.

9

Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate.

Roy EJ, Cho BK, Rund LA, Patrick TA, Kranz DM. Roy EJ, et al. Int J Cancer. 1998 May 29;76(5):761-6. doi: 10.1002/(sici)1097-0215(19980529)76:5<761::aid-ijc23>3.0.co;2-5. Int J Cancer. 1998. PMID: 9610737

10

Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.

Patrick TA, Kranz DM, Zachary JF, Roy EJ. Patrick TA, et al. Among authors: roy ej. Int J Cancer. 1998 Nov 9;78(4):470-9. doi: 10.1002/(sici)1097-0215(19981109)78:4<470::aid-ijc13>3.0.co;2-a. Int J Cancer. 1998. PMID: 9797136

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters